Last updated: October 26, 2026
Becaplermin, marketed as Regranex, is a recombinant human platelet-derived growth factor-BB gel approved for diabetic lower-extremity ulcers. Its commercial trajectory has been defined by a narrow indication, high treatment cost, safety restrictions, reimbursement pressure, and competition from advanced wound-care products. The product no longer has the growth profile of a strategic biologics asset, and public companies have not disclosed a reliable standalone revenue stream for Regranex.
What is becaplermin and what is Regranex used for?
Becaplermin is a topical recombinant human platelet-derived growth factor-BB, or rhPDGF-BB. Regranex is the 0.01% gel formulation, supplied in single-use tubes.
The FDA approved Regranex in 1997 as an adjunct to good ulcer-care practices for treating lower-extremity diabetic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. The labeled population is narrower than the total diabetic-foot-ulcer market because the product is not indicated for ischemic ulcers, pressure ulcers, venous ulcers, or all chronic wounds. [1]
Product profile
| Attribute |
Becaplermin, Regranex |
| Active ingredient |
Recombinant human platelet-derived growth factor-BB |
| Dosage form |
Topical gel |
| Strength |
0.01% |
| Original FDA approval |
1997 |
| FDA application |
NDA 020954 |
| Primary indication |
Lower-extremity diabetic ulcers |
| Administration |
Topical, generally once daily with wound care |
| Initial sponsor |
Ortho-McNeil Pharmaceutical |
| Commercial category |
Advanced wound care |
| Key safety issue |
Malignancy warning, including boxed-warning history |
| Current commercial profile |
Mature, limited, or discontinued U.S. product relative to the original launch period |
Becaplermin is not a systemic biologic administered by injection. Its commercial value depends on wound-care adoption, repeated prescription use, payer coverage, ulcer severity, and the ability of clinicians to demonstrate incremental healing benefit over standard care.
How large is the becaplermin market?
Becaplermin addresses a subset of the diabetic-foot-ulcer market rather than the full diabetic wound-care market. The addressable population is constrained by several clinical requirements:
- The ulcer must be a lower-extremity diabetic ulcer.
- The wound must have adequate perfusion.
- The ulcer must generally extend beyond the skin surface.
- The product must be used with debridement, infection control, pressure relief, and other wound-care measures.
- The clinician and payer must accept the product’s safety and cost profile.
The broader diabetic-foot-ulcer market is large because diabetes is prevalent and chronic wounds generate high hospitalization, amputation, and outpatient-care costs. Becaplermin’s product-level market has been smaller because it competes within a treatment pathway that includes debridement, offloading, infection management, negative-pressure wound therapy, cellular and tissue-based products, collagen dressings, skin substitutes, and surgical intervention.
Market drivers
The principal demand drivers have been:
- Growth in the diabetic population.
- Higher prevalence of chronic lower-extremity wounds.
- Physician demand for therapies that accelerate granulation and closure.
- Hospital and wound-center efforts to reduce amputation and recurrent care.
- Reimbursement for advanced wound-care interventions.
The principal constraints have been:
- Narrow FDA labeling.
- Requirement for adequate blood supply.
- Need for intensive standard wound care.
- Safety restrictions concerning malignancy.
- High treatment cost relative to conventional wound care.
- Competition from products with broader wound-care positioning.
- Payer scrutiny of products requiring repeated use.
What is the financial trajectory of becaplermin?
Becaplermin’s financial trajectory is best described as launch, clinical adoption, safety-related contraction, mature commercialization, and decline. No publicly reported company filing provides a consistent standalone revenue series for Regranex across its commercial life.
Financial timeline
| Period |
Commercial development |
Financial implication |
| 1997-2001 |
FDA launch and early adoption |
Initial premium pricing opportunity in diabetic wound care |
| Early to mid-2000s |
Broader wound-care commercialization |
Growth limited by narrow indication and clinical-use requirements |
| 2008 |
FDA added a boxed warning concerning malignancy risk |
Increased prescribing friction and payer scrutiny |
| 2010s |
Competition from advanced wound-care products expanded |
Reduced relative differentiation |
| Late 2010s |
U.S. availability contracted and commercial importance declined |
Lower strategic value and reduced revenue visibility |
| Current mature phase |
Limited commercial relevance compared with newer wound-care technologies |
No clear standalone growth case |
The FDA added a boxed warning in 2008 after safety analyses raised concern about increased mortality from cancer among patients receiving three or more tubes of becaplermin. The FDA stated that the absolute risk appeared low, but the signal affected the product’s benefit-risk profile and prescribing behavior. [2]
A boxed warning is commercially important even when the absolute event rate is limited. It can lead to:
- More restrictive patient selection.
- Lower treatment duration.
- Greater documentation requirements.
- Payer utilization controls.
- Substitution with non-growth-factor wound products.
- Reduced willingness to use the product in recurrent or extensive ulcers.
Revenue visibility
Regranex revenue is difficult to isolate because the product has been reported within broader wound-care portfolios rather than as a separate operating segment. Public reporting from companies associated with wound-care commercialization has generally grouped products by business unit. This prevents a reliable calculation of peak sales, cumulative sales, or current annual revenue from public filings alone. [3]
The absence of a separately disclosed revenue line is itself commercially relevant. It indicates that Regranex has not recently been material enough to warrant detailed public reporting or that it has been embedded in a wider wound-care portfolio.
What is the FDA regulatory status of becaplermin?
The FDA-approved product is Regranex gel, NDA 020954. The approved use is adjunctive treatment of diabetic lower-extremity ulcers with adequate blood supply. The label requires clinicians to apply the product to a clean ulcer and use it with appropriate wound-care practices. [1]
The principal regulatory issue is the malignancy warning. The label advises against use in patients with known malignancies at the site of application and warns about use in patients with known malignancies. The boxed warning also addresses cancer mortality observations associated with higher cumulative exposure. [1,2]
Regulatory barriers to growth
Becaplermin does not have the regulatory flexibility of a broadly labeled wound-care product. Any expansion into venous ulcers, pressure ulcers, ischemic ulcers, or other chronic wounds would require additional clinical and regulatory support. That limits the product’s ability to capture adjacent wound-care demand.
The product’s biologic manufacturing process also creates quality-control obligations. Recombinant protein production requires control of expression systems, purification, potency, identity, sterility, and stability. Those requirements are manageable for an established manufacturer but create barriers for new entrants seeking to duplicate the product.
When did becaplermin lose exclusivity?
Becaplermin’s primary commercial exclusivity has expired. The original product patents and regulatory exclusivities are no longer the principal barriers to market entry. The commercial barriers are now clinical, regulatory, manufacturing, reimbursement, and market-access related.
The FDA approved Regranex in 1997, so the five-year new chemical entity exclusivity period would have ended by 2002. Any patent protection associated with the original molecule, recombinant production, or formulation would generally have been subject to the patent terms applicable at the time of filing, with expiration dates occurring years after launch but before the current period.
Orange Book status
Regranex was approved under an NDA and was subject to FDA drug-listing and labeling requirements. Orange Book relevance centers on whether patents were listed against the NDA and whether those listings could support Paragraph IV litigation. The product’s commercial decline means that Orange Book-listed patents, if expired or no longer enforceable, do not create the same barrier that they would have created during the product’s growth phase.
A current patent-by-patent Orange Book determination cannot be made from historical commercial information alone. The key business conclusion is that Regranex is not protected today by an active exclusivity position comparable to a recently approved biologic.
Are there Paragraph IV challenges or generic entry risks?
The generic-entry risk is structurally real but commercially limited.
Becaplermin is a recombinant protein formulated as a topical gel. A competing product would need to address more than chemical sameness. It would need to demonstrate the relevant quality attributes, biological activity, formulation performance, and regulatory equivalence required by the applicable FDA pathway.
Potential competitors could pursue:
- An abbreviated pathway for a pharmaceutically equivalent topical product, if available.
- A biologics-related pathway if FDA classification and reference-product status require it.
- A full NDA pathway supported by independent clinical and manufacturing data.
- Compounding or alternative wound-care products outside direct generic substitution.
A topical biologic has greater development complexity than a conventional small-molecule cream. That may reduce the number of direct generic competitors even after patent expiry. At the same time, physicians can substitute non-becaplermin wound-care technologies without waiting for a direct generic equivalent.
No major, commercially consequential Paragraph IV campaign has defined the recent Regranex market in the way that Paragraph IV litigation has affected high-revenue oral drugs. The more important competitive risk has been therapeutic substitution.
What formulations and methods of use are protected?
The commercial product is a 0.01% topical gel used once daily as an adjunct to wound care. The relevant intellectual-property categories historically included:
- Recombinant PDGF-BB production.
- Pharmaceutical compositions containing becaplermin.
- Topical gel formulations.
- Wound-healing methods.
- Dosing and administration methods.
- Manufacturing and purification processes.
The original formulation and use claims are now mature. Any surviving patent value would depend on claim scope, terminal disclaimers, expiration status, ownership, and enforceability. The narrow labeled indication also reduces the practical value of broad patent claims if clinicians can substitute other wound-care treatments.
How strong is the becaplermin patent estate?
The patent estate is commercially weak relative to a newly launched biologic. Patent expiry has removed the main source of exclusivity, while the product’s clinical label and safety warning limit the value of any later formulation or method patents.
Patent strength can be assessed across five dimensions:
| Factor |
Assessment |
| Composition claims |
Mature and unlikely to provide current exclusivity |
| Formulation claims |
Potentially relevant historically, but limited by product maturity |
| Method-of-use claims |
Narrow because the approved indication is specific |
| Manufacturing claims |
May deter technically inexperienced entrants but do not block all alternatives |
| Regulatory exclusivity |
Expired |
The strongest remaining barrier is not patent protection. It is the cost and complexity of developing a clinically credible recombinant growth-factor product for a narrow wound-care indication.
Which companies challenge becaplermin commercially?
Becaplermin competes with product classes rather than with one direct molecule. The principal competitive groups include:
- Cellular and tissue-based products.
- Acellular dermal matrices.
- Amniotic and placental tissue products.
- Collagen and extracellular-matrix dressings.
- Negative-pressure wound therapy.
- Engineered skin substitutes.
- Conventional moist wound-healing dressings.
- Surgical debridement and offloading.
- Investigational growth factors and regenerative therapies.
Companies active in advanced wound care have included Smith & Nephew, Organogenesis, Integra LifeSciences, 3M, Mölnlycke, Convatec, and privately held tissue-product manufacturers. The relevant competition varies by wound severity, reimbursement policy, hospital purchasing arrangement, and whether the treating institution uses a wound-care center or a general outpatient model.
Becaplermin’s direct differentiation is its growth-factor mechanism. Its commercial disadvantage is that clinicians must use it within a broader care protocol, while competing products may be selected for structural coverage, exudate management, tissue support, or procedural convenience.
What patent litigation affects becaplermin?
No major recent patent litigation has established a durable barrier around Regranex comparable to litigation involving leading oncology, immunology, or diabetes biologics. Historical disputes, if any, would be more relevant to original ownership, licensing, manufacturing rights, or patent scope than to current market protection.
The absence of active high-value litigation is consistent with the product’s maturity and reduced revenue base. A company considering entry would focus more heavily on FDA pathway, manufacturing validation, reimbursement, and clinical adoption than on defending against a large active patent estate.
What licensing deals shaped becaplermin commercialization?
Regranex commercialization involved pharmaceutical and wound-care companies over its lifecycle, with marketing and portfolio ownership changing as the product moved through the industry. Public disclosures have generally treated the product as part of a wider wound-care portfolio rather than reporting a major standalone licensing transaction tied exclusively to becaplermin.
Licensing value has declined because:
- Core exclusivity has expired.
- The product has a narrow market.
- Safety labeling limits broader use.
- Newer wound-care categories have expanded.
- Standalone revenue is not publicly visible.
- Manufacturing and distribution economics are less attractive at lower volume.
A new license would likely be justified only if it provided geographic access, manufacturing capability, or portfolio synergies rather than exclusive control of a high-growth asset.
What generic launch scenarios exist for becaplermin?
Three launch scenarios are commercially plausible.
Direct topical equivalent
A manufacturer could seek approval for a product closely matching Regranex in strength, dosage form, and use. The principal challenge would be demonstrating equivalence and maintaining a validated recombinant manufacturing process.
Biologic or full-development entrant
A company could develop a new PDGF product or alternative growth-factor formulation through a more extensive regulatory pathway. This would require clinical differentiation or a meaningful cost advantage.
Therapeutic substitute
The most likely competitive route is substitution by advanced wound-care products that do not contain becaplermin. These products can erode use without a formal generic launch.
For a generic or follow-on manufacturer, commercial success would depend on reimbursement, procurement access, physician familiarity, tube-level pricing, and the ability to overcome the malignancy warning.
How does becaplermin compare with advanced wound-care alternatives?
| Attribute |
Becaplermin |
Cellular or tissue product |
Negative-pressure therapy |
Conventional dressing |
| Mechanism |
Growth-factor signaling |
Structural or cellular support |
Mechanical wound management |
Moisture and exudate control |
| FDA positioning |
Narrow diabetic-ulcer indication |
Product-specific |
Device-based |
Broad product-specific uses |
| Use setting |
Outpatient and wound centers |
Wound centers and surgery |
Hospitals and outpatient care |
Broad outpatient use |
| Main limitation |
Safety warning and narrow use |
Cost and handling |
Equipment and care burden |
Lower biological activity |
| Direct generic risk |
Moderate technical complexity |
Low to moderate |
Device competition |
High product substitution |
| Reimbursement sensitivity |
High |
High |
High |
Moderate |
Becaplermin’s value is highest when the clinician believes growth-factor stimulation will materially accelerate healing and when the payer accepts the associated cost. Its value is lowest when perfusion is poor, infection is uncontrolled, pressure is not relieved, or competing tissue products are preferred.
What is the commercial outlook for becaplermin?
The commercial outlook is mature to declining rather than expansionary. A meaningful rebound would require a new clinical positioning, a lower-cost manufacturing model, a favorable reinterpretation of safety concerns, or a new formulation with broader utility. None of those factors has been established as a current market driver.
The product may retain niche value in selected diabetic-foot-ulcer cases, particularly where clinicians are familiar with the therapy and reimbursement remains available. That niche is unlikely to support the growth rates associated with newer specialty biologics.
Key Takeaways
- Becaplermin is a topical recombinant human PDGF-BB product marketed as Regranex.
- FDA approval is limited to diabetic lower-extremity ulcers with adequate blood supply and appropriate wound care.
- The 2008 boxed warning concerning malignancy risk materially weakened adoption and commercial differentiation.
- Core patent and regulatory exclusivity have expired.
- No reliable standalone revenue series is publicly disclosed.
- Direct generic entry is technically possible but complicated by recombinant manufacturing and topical-biologic equivalence requirements.
- Therapeutic substitution from tissue products, negative-pressure therapy, collagen products, and other advanced wound-care technologies is the principal competitive threat.
- The current asset profile is mature, niche, and reimbursement-sensitive.
- Patent litigation and licensing are unlikely to be the primary determinants of near-term value.
- The main commercial barriers are clinical adoption, safety perception, manufacturing economics, reimbursement, and competition from alternative wound-care modalities.
FAQs About Becaplermin
Is becaplermin still FDA approved?
Regranex received FDA approval under NDA 020954. Its current commercial availability is materially narrower than during the original launch period, and market access depends on product supply, distribution, and payer coverage.
Is becaplermin a biosimilar?
No. Becaplermin is the active recombinant growth factor in Regranex. A future follow-on product would need to satisfy the FDA requirements applicable to the product’s regulatory classification and dosage form.
Can becaplermin be used for venous leg ulcers?
The FDA-approved indication is for lower-extremity diabetic ulcers with adequate blood supply. Use outside the approved indication would be off-label and would not carry the same labeled regulatory support.
Why did Regranex sales decline?
The principal factors were the narrow indication, the FDA malignancy warning, treatment cost, reimbursement controls, product maturity, and competition from newer wound-care technologies.
Does becaplermin have meaningful remaining patent value?
The original exclusivity position has expired. Any remaining patent value would depend on specific formulation, manufacturing, or method claims, but those claims are unlikely to create a broad current market barrier.
References
- U.S. Food and Drug Administration. (2008). Regranex (becaplermin) gel prescribing information.
- U.S. Food and Drug Administration. (2008). FDA public health advisory: Regranex and cancer mortality risk.
- Smith & Nephew plc. (2018). Annual report and accounts 2018.
- U.S. Food and Drug Administration. (1997). Approval letter for Regranex, NDA 020954.
- National Institute for Health and Care Excellence. (2019). Diabetic foot problems: Prevention and management. NICE guideline NG19.
